Merck (MRK) Q3 2026 Earnings Call Transcript
On its third-quarter 2026 earnings call, Merck discussed generic headwinds ahead in 2027 alongside new product launches and growth of its WINREVAIR medicine.
fool.com ·
24/7
-
-sur la période sélectionnée
-depuis la clôture américaine
Écarts de prix avant frais et coûts d’exécution. Comparer les prix
On its third-quarter 2026 earnings call, Merck discussed generic headwinds ahead in 2027 alongside new product launches and growth of its WINREVAIR medicine.
fool.com ·
Benzinga reported that Merck beat Q3 estimates on oncology strength and raised guidance, and that Guggenheim is watching pipeline progress ahead of Keytruda patent loss.
benzinga.com ·